linezolid TB
Selected indexed studies
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. (N Engl J Med, 2022) [PMID:36053506]
- Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. (J Antimicrob Chemother, 2018) [PMID:29584861]
- Drug resistant TB - latest developments in epidemiology, diagnostics and management. (Int J Infect Dis, 2022) [PMID:35342000]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. (2022) pubmed
- Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. (2018) pubmed
- Drug resistant TB - latest developments in epidemiology, diagnostics and management. (2022) pubmed
- Linezolid resistance in patients with drug-resistant TB. (2023) pubmed
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. (2020) pubmed
- Treatment Strategy for Rifampin-Susceptible Tuberculosis. (2023) pubmed
- Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis. (2022) pubmed
- Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. (2025) pubmed
- Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. (2018) pubmed
- Toxic neuropathies. (2023) pubmed